<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03271814</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00076657</org_study_id>
    <nct_id>NCT03271814</nct_id>
  </id_info>
  <brief_title>Brain Biomarker on Inflammation Response</brief_title>
  <acronym>LPS</acronym>
  <official_title>Brain Biomarker on Inflammation Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a double-blinded, randomized, parallel controlled design, patients with schizophrenia&#xD;
      spectrum disorder will be exposed to a single dose of lipopolysaccharide (LPS) (LPS-patient).&#xD;
      Clinical symptoms, blood samples, and brain imaging will be assessed at baseline and after&#xD;
      LPS. There will be two comparison groups. Comparison groups include an age- and sex-matched&#xD;
      healthy control group also exposed to the same LPS (LPS-control), and an age- and sex-matched&#xD;
      sample of patients with schizophrenia on placebo (Placebo-patient). As in Phase I studies,&#xD;
      multiple interim analyses are expected so the current design may be modified, which will be&#xD;
      communicated during annual reports (21CFR312.30).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Schizophrenia spectrum disorders are a major public health burden due to functional and&#xD;
      cognitive impairment, psychosis and other symptoms, and high comorbidity. Unfortunately,&#xD;
      current therapies have limited effectiveness in treating some of the symptoms and most of the&#xD;
      cognitive deficits. Alternative biological models of the disease are needed for developing&#xD;
      new and more effective treatment. Neuroinflammation has increasingly been implicated in the&#xD;
      pathophysiology of schizophrenia. Patients with schizophrenia have signs of low-grade,&#xD;
      chronic inflammation, including elevated blood levels of pro-inflammatory cytokines and other&#xD;
      immune markers. Administration of LPS is the standard immune challenge to investigate the&#xD;
      body's immune response in a wide range of disorders. Our goal is to use LPS to investigate&#xD;
      whether schizophrenia patients have abnormal immune response to LPS and whether the&#xD;
      abnormality is associated with specific brain imaging biomarkers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2023</start_date>
  <completion_date type="Anticipated">December 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IL-6</measure>
    <time_frame>Hourly for 6 hours</time_frame>
    <description>Cytokine IL-6 at baseline and response to LPS challenge (to be reported in pg/ml or IU/ml)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Brain imaging structure and function via MRI</measure>
    <time_frame>3 to 6 hours</time_frame>
    <description>Brain imaging at baseline and response to LPS challenge (to be reported in institutional units)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>LPS-Patient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Schizophrenia patients who are randomized to receive LPS injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS-Healthy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls who are randomized to receive LPS injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-Patient</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Schizophrenia patients who are randomized to receive placebo injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LPS</intervention_name>
    <description>0.6 by/kg LPS single dose iv</description>
    <arm_group_label>LPS-Healthy</arm_group_label>
    <arm_group_label>LPS-Patient</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sterile Water</description>
    <arm_group_label>Placebo-Patient</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-55&#xD;
&#xD;
          2. Patients must be on antipsychotic medication and clinically stable, defined as no&#xD;
             hospitalization or major change in antipsychotic medication in the past 4 weeks&#xD;
&#xD;
          3. Patients must pass the ESC with score 10 or above&#xD;
&#xD;
          4. BMI 35 or less -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of major medical illness including, but not limited to, history of heart&#xD;
             attack, stroke, TIA (transient ischemic attack)&#xD;
&#xD;
          2. History of organic brain disorders that may affect neurophysiological measurements,&#xD;
             including seizure disorder, brain tumor, head injury with evidence of significant&#xD;
             cognitive deterioration&#xD;
&#xD;
          3. DSM diagnosis of substance use disorder within 6 months except nicotine and marijuana&#xD;
&#xD;
          4. Prior suicide attempt or frequent suicidal ideations, or current suicidal ideation&#xD;
             assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)&#xD;
&#xD;
          5. Women who have positive urine pregnancy tests; Women who plan to become pregnant, or&#xD;
             are breastfeeding&#xD;
&#xD;
          6. Frequent (more than once) history of syncope (fainting) of unknown reason&#xD;
&#xD;
          7. Unable to undergo MRI scanning due to metallic devices or objects or claustrophobia&#xD;
&#xD;
          8. Presence of co-morbid inflammatory disorders such as rheumatoid arthritis&#xD;
&#xD;
          9. Presence of acute or chronic infection; have received flu or similar vaccine in the&#xD;
             past 4 weeks&#xD;
&#xD;
         10. Current regular use of non-steroidal anti-inflammatory drugs or immune modifying drugs&#xD;
&#xD;
         11. Clinically significant abnormalities on screening laboratory tests&#xD;
&#xD;
         12. Blood pressure &lt;90/60 or &gt; 150/100, or pulse &lt;55 or &gt; 100 beats/minute, or temperature&#xD;
             &gt; 99.5Â°F&#xD;
&#xD;
         13. 12-Lead ECG demonstrating QTcF &gt;450 msec or a QRS interval &gt;120 msec. If QTcF exceeds&#xD;
             450 msec, or QRS exceeds 120 msec, the ECG should be repeated two more times and the&#xD;
             average of the three QTcF values should be used to determine the subject's eligibility&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>L E Hong, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, Baltimore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Liu, RN, MSN</last_name>
    <phone>410-402-6832</phone>
    <email>jliu@mprc.umaryland.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dawn R Detamore</last_name>
    <phone>410-402-6820</phone>
    <email>ddetamor@mprc.umaryland.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Maryland, Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>August 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>L. Elliot Hong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

